

August 12, 2025

Sawai Group Holdings Co., Ltd.

**Notice Regarding the Expansion of Production Capacity at Trust Pharmatech's Seima Plants  
– Group to Manufacture 25 billion Tablets by Fiscal Year 2030 –**

Sawai Group Holdings Co., Ltd. (Head office: Yodogawa-ku, Osaka; Representative Director and President: Mitsuo Sawai; hereinafter, “Sawai Group”) hereby announces a decision to expand production capacity at Seima Plants No. 2 and No. 3 of its group subsidiary, Trust Pharmatech Co., Ltd. (Head office: Awara-shi, Fukui; President: Toshiya Hasuo; hereinafter, “Trust Pharmatech”).

Currently, Trust Pharmatech has the capability to produce 3 billion tablets per year. To expand production capacity, Seima Daini Factory will utilize unused space, to add new formulation equipment, increasing its annual capacity by 1 billion tablets. Seima Daisan Factory will use the existing building to become a new production factory that can have the capability to produce 1.5 billion tablets. With this initiative, we aim to respond to the growing demand for our products, driven by recent quality and supply issues in the generics drugs industry, and strengthen the production capabilities to prepare for further market expansion of generic drugs.

The Sawai Group aims to establish an in-house production structure with a capacity of 24.5 billion tablets. This will be achieved from the new solid formulation operation at Sawai Pharmaceutical's Daini Kyushu Factory, which began shipments in December 2024, step 2 of Daini Kyushu Factory scheduled for fiscal year 2026, and the increase of production capacity at Seima Daini Factory and Seima Daisan Factory in 2027. We will continue to strengthen our stable supply capabilities as described in the three-year medium-term management plan, “Beyond 2027,” and work toward achieving our long-term vision of establishing a production capability exceeding 25 billion tablets by fiscal year 2030.

With the corporate philosophy of “Dedicated to building a healthier future for all,” Sawai Group is working to solve social issues through the realization of a sustainable society with the generic drugs business as its core business. Going forward, to fulfill our responsibilities as a leading generic drug manufacturer, we will continue to explore a wide range of opportunities with an extensive and flexible approach, and work to deliver safe and high-quality products to all those who need generic drugs.

■ Outline of the factories and upcoming schedule

|                                  |                                           |
|----------------------------------|-------------------------------------------|
| Name                             | Trust Pharmatech’s Seima Factory 2        |
| Location                         | 11-15 Seima, Awara City, Fukui Prefecture |
| Additional production capability | 1 billion tablets                         |
| Planned investment amount        | 4.6 billion yen                           |



|          |                                                                                                                     |
|----------|---------------------------------------------------------------------------------------------------------------------|
| Name     | Trust Pharmatech's Seima Factory 2                                                                                  |
| Schedule | September 2025: Start construction<br>March 2027: Complete construction<br>End of 2027: Start commercial production |



|                                  |                                                                                                    |
|----------------------------------|----------------------------------------------------------------------------------------------------|
| Name                             | Trust Pharmatech's Seima Factory 3                                                                 |
| Location                         | 20-22-1 Seima, Awara City, Fukui Prefecture                                                        |
| Additional production capability | 1.5 billion tablets                                                                                |
| Planned investment amount        | 14.9 billion yen                                                                                   |
| Schedule                         | March 2026: Start construction<br>October 2027: Complete construction<br>July 2029: First shipment |

■ **Outline of Trust Pharmatech Co., Ltd.**

|                         |                                          |
|-------------------------|------------------------------------------|
| Company name            | Trust Pharmatech Co., Ltd.               |
| Date of establishment   | December 3, 2021                         |
| Capital                 | 101 million yen                          |
| Main business           | Manufacturing of ethical pharmaceuticals |
| Representative Director | Toshiya Hasuo                            |

◆ Contact Information ◆

IR Group, Sawai Group Holdings Co., Ltd.  
TEL: +81-6-6105-5823 / E-mail: [ir@sawaigroup.holdings](mailto:ir@sawaigroup.holdings)